When was Hansa Biopharma founded?

Hansa Biopharma was founded in 2007 and raised its 1st funding round 10 years after it was founded.

Where is Hansa Biopharma located?

Hansa Biopharma is headquartered in Lund, Sweden. It is registered at Scheelevägen 22, SE-220 07 LUND.

Which legal entities is Hansa Biopharma associated with?

Hansa Biopharma is associated with HANSA BIO and 2 others.

How many employees does Hansa Biopharma have?

As of May 31, 2026, the latest employee count at Hansa Biopharma is 146.

Is Hansa Biopharma a funded company?

Hansa Biopharma is a funded company, having raised an undisclosed amount across 4 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Nov 29, 2017.

When was the latest funding round of Hansa Biopharma?

Hansa Biopharma's latest funding was a $***** Post IPO round on Mar 20, 2026, with participation from 1 investor.

Where does Hansa Biopharma rank among its competitors?

Hansa Biopharma ranks 38th amongst 299 active competitors, of which 122 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Viridian Therapeutics, which secured $20M in May, 2026.

Who are the top competitors of Hansa Biopharma?

Hansa Biopharma's top competitors include TScan Therapeutics, Viridian Therapeutics and Dren Bio. Among them, Viridian Therapeutics secured the most recent funding round in May, 2026.

Hansa Biopharma - 2026 Company Profile, Funding & Competitors

Company Details

Developer of therapeutics to treat rare immunological diseases. The company is developing and commercializing immunomodulating therapies across transplantation, autoimmune diseases, gene therapy, and oncology indications.

Website: hansabiopharma.com
Email ID: *****@hansamedical.com
Phone Number: +46 **********
Registered Address: Scheelevägen 22, SE-220 07 LUND

Key Metrics

Founded Year

2007

Location

Lund, Sweden

Stage

Public

Latest Funding Round

Post IPO, Mar 20, 2026, $*****

Investors

Athyrium Capital Management & 2 more

Ranked

38^th among 299 active competitors

Employee Count

146 as on May 31, 2026

Investment & Acquisitions

Immago Biosystems & 1 more

Similar Companies

TScan Therapeutics & 325 more

Exit Details

Public

View Hansa Biopharma's full profile

Hansa Biopharma is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
HANSA BIO CIN: 40103899653 , Latvia, Active	May 18, 2015	$84.1K (As on Dec 31, 2024)	2 (As on Dec 31, 2022)	-
HANSA BIOPHARMA AB CIN: 925873667 , Norway, Active	Jun 04, 2007	-	-
HANSA SALES CIN: 40103812575 , Latvia, Active	Jul 30, 2014	$23.2K (As on Dec 31, 2024)	1 (As on Dec 31, 2022)	-

Hansa Biopharma got listed on Oct 19, 2007.

Click here to take a look at Hansa Biopharma's IPO in detail

Hansa Biopharma has raised funding over 4 rounds. Its first funding round was on Nov 29, 2017. Its latest funding round was a Post IPO round on Mar 20, 2026 for $*****. 1 investor participated in its latest round. Hansa Biopharma has 3 institutional investors.

Here is the list of recent funding rounds of Hansa Biopharma:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 20, 2026	3559374	Post IPO	7454689	8405552	9149303	2078287
Jul 19, 2022	4218018	Post IPO	9385656	9340566	9413205	NovaQuest Capital Management
Jul 08, 2020	1626485	Post IPO	3244408	4942398	4918185	9111311

Access funding benchmarks and valuations. Sign up today!

View details of Hansa Biopharma's funding rounds and investors

Hansa Biopharma's employee count trend

Hansa Biopharma has 146 employees as of May 26. Here is Hansa Biopharma's employee count trend over the years:

Employee count trend for Hansa Biopharma

Uncover Hansa Biopharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Hansa Biopharma include TScan Therapeutics, Viridian Therapeutics and Dren Bio. Here is the list of Top 10 competitors of Hansa Biopharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	TScan Therapeutics 1995, Boston (United States), Public	Developer of T cell therapies to harness the immune system against cancer	$180M	BlackRock, Novartis & 9 others	70/100
2nd	Viridian Therapeutics 2007, Boulder (United States), Public	Developer of medicines for patients with serious and rare diseases	$14.5M	Fairmount Funds Management, MRLV & 2 others	69/100
3rd	Dren Bio 2019, San Carlos (United States), Series B	Developer of therapeutic antibodies for the treatment of cancer, autoimmune, and other serious diseases	$156M	Taiho Ventures, 8VC & 13 others	68/100
4th	Aurinia Pharmaceuticals 1993, Edmonton (Canada), Public	Developer of therapeutics for autoimmune diseases	-	Abingworth, Lumira Ventures & 10 others	67/100
5th	Autolus 2015, London (United Kingdom), Public	Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases	$181M	Syncona, Blackstone & 7 others	65/100
6th	Quell 2019, London (United Kingdom), Series B	Developer of engineered regulatory T cell therapies for immune diseases	$344M	Syncona, SV Health Investors & 17 others	65/100
7th	Horizon Therapeutics 2008, Dublin (Ireland), Acquired	Developer of drugs for treating rare and autoimmune diseases	$61.8M	NGN Capital, Atlas Venture & 4 others	64/100
8th	Sonoma Biotherapeutics 2012, San Francisco (United States), Series B	Developer of T-cell-based therapies for autoimmune and degenerative diseases	$335M	Lilly Asia Ventures, Arch Venture Partners ... & 20 others	64/100
9th	Q32 Bio 2018, Cambridge (United States), Public	Developer of drugs for treating autoimmune disorders	$106M	Atlas Venture, Orbimed & 9 others	63/100
10th	Cue Biopharma 2015, Cambridge (United States), Public	Precision immunotherapies to transform patients' lives by selectively modulating the immune system	$26.4M	MDB Capital	63/100
38th	Hansa Biopharma 2007, Lund (Sweden), Public	Developer of therapeutics to treat rare immunological diseases	-	Nxt2b, NovaQuest Capital Management & 1 others	58/100